Medicine details

ImageDinakion
NameDinakion
DosageInjection
Generic NamePhytomenadione
Classes Vitamin
Vitamin Analogue
Diseases
CompanyDrug International Ltd.

Drug Package Details

Strength2 mg/.2 ml
Storage Condition
Origin CountryBangladesh
Commercial Pack5
Price per pack99.45
Cost per pack87.52
Package unit0.2 ml amp
Price per unit19.89
Cost per unit17.50
Discount0
Coupon
Remarks

Phytomenadione

Phytomenadione or Vitamin K plays a key role in blood clotting , preventing excessive bleeding. Unlike many other vitamins, vitamin K is not typically used as a nutritional supplement. Vitamin K is actually a group of compounds, the most important of these compounds appears to be vitamin K1 and vitamin K2. Vitamin K1 is obtained from leafy greens and some other vegetables. Vitamin K2 is a group of compounds largely obtained from meats, cheeses, and eggs, and synthesized by bacteria.

Vitamin K is indicated for the following conditions-

  • Hemorrhagic diseases in children
  • Severe hypoprothrombinemia
  • Overdosage of courmarin-type anticoagulants
  • Bleeding 

 

Mild Hemorrhage or Hemorrhagic Tendency: The usual dose for neonates is 2 mg orally at or shortly after birth. Then, on the fourth and fifth days, take 2 mg orally, followed by another 2 mg on the 28th and 30th days. If the oral route is not suitable, 2 mg of drug can be administered intravenously (IM) or intravenously (IV).

Children over the age of one year: 5-10 mg orally. In children who cannot be assured of receiving a second oral dose or, in the case of breast-fed children, a third oral dose, a single 1 mg (0.1 ml) dose IM is recommended.


Therapy: 1 mg intravenous injection initially, with additional doses as needed based on clinical picture and coagulation status.

Neonates with special risk factors: Prematurity, birth asphyxia (inadequate oxygen intake by the baby during the birth process), obstructive jaundice, inability to swallow, maternal use of anticoagulants or anti-epileptics-

  • 1 mg intramuscularly or intravenously at birth or shortly after birth if the oral route is ineffective.
  • In premature infants weighing less than 2.5 kg, intramuscular and intravenous doses should not exceed 0.4 mg/kg.
  • The size and frequency of subsequent doses should be determined by coagulation status.

To ensure complete protection for newborns, three prophylactic doses of Vitamin K should be administered orally in accordance with the dosing schedule outlined above.

Following side effect may appear-

  • Phlebitis
  • Irritation
  • hypotension
  • rash
  • For patients with severely impaired liver function following Phytomenadione administration, careful monitoring of coagulation parameters is required.
  • Even when precautions were taken to dilute the phytonadione and avoid rapid infusion, severe reactions, including fatalities, have occurred during and immediately after INTRAVENOUS injection of phytonadione. Following INTRAMUSCULAR administration, severe reactions, including fatalities, have also been reported. These severe reactions, which have typically resembled hypersensitivity or anaphylaxis, have included shock and cardiac and/or respiratory arrest. Some patients experienced severe reactions after receiving phytonadione for the first time. As a result, the INTRAVENOUS and INTRAMUSCULAR routes should be used only when the subcutaneous route is not feasible and the serious risk involved is deemed justified.

Contraindication

Contraindicated in patients hypersensitive to any component of the formulation.

There is no known contraindications of the preparation in terms of food and drinks.

There is no known contraindications of the preparation in terms of health conditions.